Congestive heart failure is a chronic disease. One of the challenges in managing patients with heart failure is developing methods of assessing the severity of each patient’s illness and tailoring treatment to match it. At present, there are numerous modalities used to describe patients in heart failure. The clinical history, examination, laboratory tests, radiographs, functional, and invasive ...

B-type natriuretic peptide (BNP) is a 32 amino acid cardiacsynthesized hormone that reduces blood pressure and increases sodium excretion (1 ). Following proteolytic cleavage of proBNP, a 108-amino acid precursor, an Nterminal fragment (NT-proBNP) and BNP are released (2 ). Increased concentrations of BNP and NT-proBNP can be used clinically to monitor heart failure, but a lack of alignment bet...

B-type natriuretic peptide (BNP) is an established biomarker for the differentiation of acute dyspnoea in the emergency department. However, evidence for BNP testing in outpatients is less strong. BNP is not a global test to detect cardiac abnormalities and is only helpful in a few clearly defined clinical settings. Similarly to its use in emergency department patients, BNP is useful in outpati...

Gene expression and secretion of the cardiac polypeptide hormones atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) are simultaneously upregulated in various cardiac disorders such as congestive heart failure, ischemic heart disease, and hypertensive heart disease, in which hemodynamic or neuroendocrine changes are key components in the progression of disease. However, during ...

BACKGROUND Despite effective treatment with anticoagulants, 2% to 7% of patients with pulmonary embolism will die as a result of their disease. METHODS AND RESULTS We examined in 110 consecutive patients with pulmonary embolism whether plasma brain natriuretic peptide (BNP), a novel marker of (right) ventricular dysfunction, is a predictor of fatal pulmonary embolism. The relationship between...

Cardiovascular biomarkers provide independent prognostic information in the assessment of mortality and cardiovascular complications. However, little is known about possible interactions between these biomarkers. In the present study, we evaluated the influence of B-type natriuretic peptide (BNP) on midregional-proadrenomedullin (MR-proADM), C-terminal-proendothelin-1 (CT-proET-1), growth diffe...

We read with great interest the article by Cowie et al.1 on clinical applications of the assessment of B-type natriuretic peptide (BNP). This is an important subject and the article also helps to clarify which areas of BNP research need more attention. The authors conclude that in new patients presenting to emergency services with dyspnoea, if the BNP level is <100 pg/mL, then heart failure is ...

Results Baseline BNP, TnI and CKMB levels were 105.8 pg/ml, 0.9 ng/ml and 2.34 ng/ml. Although all biomarkers increased significantly within 6 hours of surgery, release kinetics were different. While peak BNP levels occurred in 96% patients by 24-48 hours, for TnI and CKMB, this was observed in only two-thirds. A trend towards fall in all biomarkers was seen by 48 hours; while TnI and CKMB leve...

OBJECTIVES To clarify the role of infarct and non-infarct sites on left ventricular (LV) remodelling after myocardial infarction by measuring brain natriuretic peptide (BNP) from each site. METHODS AND RESULTS BNP from the aorta and the anterior interventricular vein (AIV) was measured in 45 patients with first anterior myocardial infarction at one, six, and 18 months. The LV was significantl...